[Demographic analysis of a congenital heart disease clinic of the Mexican Institute of Social Security, with special interest in the adult]. / Análisis demográfico de una clínica de cardiopatías congénitas del Instituto Mexicano del Seguro Social, con interés en el adulto.

INTRODUCTION: Congenital heart disease (CHD) has an incidence of 8-10 cases per 1000 live births. In Mexico, there are 18,000-20,000 new cases per year. Most tertiary care centers for CHD attend only pediatric population; the Mexican Institute of Social Security (IMSS) has a clinic that attends pediatric and adult population. OBJECTIVE: To analyze the demographic aspects of the CHD clinic of IMSS. METHODS: From 2011 to 2016 a cross-sectional study of the CC clinic of a third level hospital of the IMSS, including all patients with confirmed structural heart disease of recent diagnosis was carried out. The sex, age, reference entity, antecedent of pregnancy and treatment were registered. The population was divided into age ranges (<2 years, 2.1-6 years, 6.1-10 years, 10.1-17 years and >17.1 years). Descriptive statistics and χ2 test were used in qualitative variables. RESULTS: 3,483 patients with CHD (male:female ratio, 0.8:1.2) were included. Increased pulmonary flow acyanogenic cardiopathies were the most frequent CHD group (47.2%), with atrial septal defect being the most frequent diagnosis overall; 25.6% were adults and 35% of women with a history of pregnancy. Chiapas was Federal entity with greater proportion of patients diagnosed in the adult stage (33.82%); 7% were not candidates for any treatment for complications of the disease. CONCLUSIONS: CHD is a late diagnosis; it is necessary to create a national register to promote new health policies and a rational distribution of resources for these patients.

Análisis demográfico de una clínica de cardiopatías congénitas del Instituto Mexicano del Seguro Social, con interés en el adulto / Demographic analysis of a congenital heart disease clinic of the Mexican Institute of Social Security, with special interest in the adult

Resumen Introducción: Las cardiopatías congénitas (CC) en México se presentan con una cifra estimada entre 18,000-20,000 nuevos casos por año. La mayor parte de los centros que atienden a estos enfermos son exclusivamente pediátricos y el Instituto Mexicano del Seguro Social (IMSS) cuenta con una clínica que atiende a todas las edades. Objetivo: Analizar los aspectos demográficos de una clínica de CC del niño y del adulto del IMSS. Métodos: De 2011 a 2016 se realizó un estudio transversal de la clínica de CC de un hospital de tercer nivel del IMSS, incluyendo todos los pacientes con cardiopatía estructural confirmada de reciente diagnóstico. Se registró el sexo, la edad, la entidad federativa de referencia, el antecedente de embarazo y el tratamiento. Se dividió a la población en rangos de edades (< 2 años, 2.1-6 años, 6.1-10 años, 10.1-17 años y > 17.1 años). Se empleó estadística descriptiva y prueba de y2 en las variables cualitativas. Resultados: Tres mil cuatrocientos ochenta y tres enfermos con CC (relación hombre:mujer,0.8:1.2), las cardiopatías acianógenas de flujo pulmonar aumentado son el grupo más grande (47.2%); 25.6% fueron adultos y 35% de las mujeres con antecedente de al menos una gesta. En general la cardiopatía más frecuente fue la comunicación interauricular. La entidad federativa con mayor frecuencia de adultos de reciente diagnóstico fue Chiapas (33.82%); el 7% no fueron candidatos a ningún tratamiento por complicaciones inherentes a la cardiopatía. Conclusiones: Existe un diagnóstico tardío de la atención de las CC en la etapa adulta. Es necesario crear un registro nacional para promover nuevas políticas de salud y distribución de recursos destinados a estos pacientes.

Abstract Introduction: Congenital heart disease (CHD) has an incidence of 8-10 cases per 1000 live births. In Mexico, there are 18,000-20,000 new cases per year. Most tertiary care centers for CHD attend only pediatric population; the Mexican Institute of Social Security (IMSS) has a clinic that attends pediatric and adult population. Objective: To analyze the demographic aspects of the CHD clinic of IMSS. Methods: From 2011 to 2016 a cross-sectional study of the CC clinic of a third level hospital of the IMSS, including all patients with confirmed structural heart disease of recent diagnosis was carried out. The sex, age, reference entity, antecedent of pregnancy and treatment were registered. The population was divided into age ranges (< 2 years, 2.1-6 years, 6.1-10 years, 10.1-17 years and > 17.1 years). Descriptive statistics and y2 test were used in qualitative variables. Results: 3,483 patients with CHD (male:female ratio, 0.8:1.2) were included. Increased pulmonary flow acyanogenic cardiopathies were the most frequent CHD group (47.2%), with atrial septal defect being the most frequent diagnosis overall; 25.6% were adults and 35% of women with a history of pregnancy. Chiapas was Federal entity with greater proportion of patients diagnosed in the adult stage (33.82%); 7% were not candidates for any treatment for complications of the disease. Conclusions: CHD is a late diagnosis; it is necessary to create a national register to promote new health policies and a rational distribution of resources for these patients.

[Training of institutional research networks as a strategy of improvement]. / Formación de redes institucionales de investigación como una estrategia de mejora.

The Instituto Mexicano del Seguro Social (IMSS) through the Coordinación de Investigación en Salud (Health Research Council) has promoted a strong link between the generation of scientific knowledge and the clinical care through the program Redes Institucionales de Investigación (Institutional Research Network Program), whose main aim is to promote and generate collaborative research between clinical, basic, epidemiologic, educational, economic and health services researchers, seeking direct benefits for patients, as well as to generate a positive impact on institutional processes. All of these research lines have focused on high-priority health issues in Mexico. The IMSS internal structure, as well as the sufficient health services coverage, allows the integration of researchers at the three levels of health care into these networks. A few years after their creation, these networks have already generated significant results, and these are currently applied in the institutional regulations in diseases that represent a high burden to health care. Two examples are the National Health Care Program for Patients with Acute Myocardial Infarction "Código Infarto", and the Early Detection Program on Chronic Kidney Disease; another result is the generation of multiple scientific publications, and the promotion of training of human resources in research from the same members of our Research Networks. There is no doubt that the Coordinación de Investigación en Salud advances steadily implementing the translational research, which will keep being fruitful to the benefit of our patients, and of our own institution.

El Instituto Mexicano del Seguro Social (IMSS), a través de la Coordinación de Investigación en Salud, ha promovido el vínculo entre la generación de conocimiento científico y la actividad asistencial mediante el programa de Redes Institucionales de Investigación, cuyo objetivo principal es la promoción y generación de trabajo de investigación colaborativo entre investigadores del área clínica, básica, epidemiológica, educativa y en economía y sistemas de salud, buscando siempre obtener productos que tengan aplicación directa sobre los pacientes y generen un impacto positivo en los procesos institucionales. Todas las líneas de investigación se enfocan en los temas prioritarios de salud de México. La estructura interna del IMSS y la vasta cobertura de servicios que ofrece permiten incluir en estas redes a personal de los tres niveles de atención médica. A pocos años de su creación, estas redes han generado importantes resultados que se aplican en la normativa institucional en enfermedades con alta carga asistencial y económica; por ejemplo, el programa "Código Infarto" y el Programa de Detección Temprana de Enfermedad Renal Crónica; otro resultado son las múltiples publicaciones científicas y la promoción de la formación de recursos humanos en investigación de los mismos integrantes de nuestras redes de investigación. Sin duda, la Coordinación de Investigación en Salud avanza a grandes pasos en la implementación cada vez más sólida de la investigación traslacional, que seguirá dando frutos en beneficio de nuestros pacientes y de la propia institución.

[Network Research on Human Papillomavirus]. / Red de Investigación en Virus del Papiloma Humano.

In order to increase the research in important health questions at a national and institutional levels, the Human Papillomavirus Research Network of the Health Research Coordination of the Instituto Mexicano del Seguro Social offers this supplement with the purpose of assisting patients that daily look for attention due to the human papillomavirus or to cervical cancer.

A fin de incrementar la investigación en temas prioritarios de salud a nivel nacional e institucional, la Red de Investigación del Virus del Papiloma Humano de la Coordinación de Investigación en Salud del Instituto Mexicano del Seguro Social ofrece este suplemento con el objetivo de beneficiar a las pacientes que día a día se atienden por el virus de papiloma humano o por el cáncer cervicouterino.

Desarrollo y validación de la Escala de Mortalidad Neonatal-9 México para predecir la mortalidad en neonatos críticamente enfermos / Development and validation of the Neonatal Mortality Score-9 Mexico to predict mortality in critically ill neonates

Introducción. Las escalas pronósticas son de utilidad para el médico que ejerce en las unidades de cuidados intensivos neonatales. Existen escalas neonatales validadas, en su mayoría para neonatos de bajo peso al nacer. El objetivo fue crear y validar una escala predictora de mortalidad en neonatos que incluyera nuevas variables pronósticas. Población y métodos. Se realizó el estudio en un hospital materno-infantil de la ciudad de México, del Instituto Mexicano del Seguro Social. En la primera fase, se diseñó un estudio de casos y controles anidado en una cohorte (neonatos ingresados con criterios de gravedad durante el primer día de vida), en el que se identificó y construyó una escala con parámetros graduales de puntuación acumulativa de nueve variables independientes para predecir muerte: peso, acidemia metabólica, lactato, paO2/FiO2, p(A-a) O2, A/a, plaquetas y glucosa sérica. La validación se realizó en una cohorte prospectiva, de las mismas características, tomando como variable de desenlace la mortalidad hasta el séptimo día. Resultados. La cohorte incipiente estuvo conformada por 424 neonatos. Se seleccionaron 22 casos y 132 controles, y se identificaron 9 variables, que conformaron la escala nombrada escala de mortalidad neonatal-9 México. La cohorte de validación estuvo integrada por 227 neonatos. Se registraron 44 (19%) defunciones, con un área bajo la curva de 0,92. Con una puntuación de entre 16 y 18, se reportó un hazard ratio de 85 (11-102), una especificidad de 99%, un valor predictivo positivo de 71% y un valor predictivo negativo de 90%. Conclusiones. La escala propuesta es un instrumento fiable para predecir la gravedad en neonatos.

Introduction. Prognostic scales or scores are useful for physicians who work in neonatal intensive care units. There are several validated neonatal scores but they are mostly applicable to low birth weight infants. The aim of this study was to develop and validate a mortality prognostic score in newborn infants, that would include new prognostic outcome measures. Population and Methods. The study was conducted in a mother and child hospital in the city of Mexico, part of the Instituto Mexicano del Seguro Social (Mexican Institute of Social Security). In the first phase of the study, a nested case-control study was designed (newborn infants admitted on the basis of severity criteria during the first day of life), in which a scale was identified and developed with gradual parameters of cumulative score consisting of nine independent outcome measures to predict death, as follows: weight, metabolic acidemia, lactate, PaO2/FiO2, p(A-a) O2, A/a, platelets and serum glucose.Validation was performed in a matched prospective cohort, using 7-day mortality as an endpoint. Results. The initial cohort consisted of 424 newborn infants. Twenty-two cases and 132 controls were selected; and 9 outcome measures were identified, making up the scale named neonatal mortality score-9 Mexico. The validation cohort consisted of 227 newborn infants. Forty-four (19%) deaths were recorded, with an area under the curve (AUC) of 0.92. With a score between 16 and 18, an 85 (11-102) hazard ratio, 99% specificity, 71% positive predictive value and 90% negative predictive value were reported. Conclusions .The proposed scale is a reliable tool to predict severity in newborn infants.

Development and validation of the Neonatal Mortality Score-9 Mexico to predict mortality in critically ill neonates.

INTRODUCTION: Prognostic scales or scores are useful for physicians who work in neonatal intensive care units. There are several validated neonatal scores but they are mostly applicable to low birth weight infants. The aim of this study was to develop and validate a mortality prognostic score in newborn infants, that would include new prognostic outcome measures. POPULATION AND METHODS: The study was conducted in a mother and child hospital in the city of Mexico, part of the Instituto Mexicano del Seguro Social (Mexican Institute of Social Security). In the first phase of the study, a nested case-control study was designed (newborn infants admitted on the basis of severity criteria during the first day of life), in which a scale was identified and developed with gradual parameters of cumulative score consisting of nine independent outcome measures to predict death, as follows: weight, metabolic acidemia, lactate, PaO2/FiO2, p(A-a) O2, A/a, platelets and serum glucose.Validation was performed in a matched prospective cohort, using 7-day mortality as an endpoint. RESULTS: The initial cohort consisted of 424 newborn infants. Twenty-two cases and 132 controls were selected; and 9 outcome measures were identified, making up the scale named neonatal mortality score-9 Mexico. The validation cohort consisted of 227 newborn infants. Forty-four (19%) deaths were recorded, with an area under the curve (AUC) of 0.92. With a score between 16 and 18, an 85 (11-102) hazard ratio, 99% specificity, 71% positive predictive value and 90% negative predictive value were reported. Conclusions .The proposed scale is a reliable tool to predict severity in newborn infants.

Evaluación de la función ventricular y auricular derecha con ecocardiografía 3D en tromboembolia pulmonar aguda / Assessment of right ventricular and atrial function with 3D echocardiography in acute pulmonary embolism

Introducción: La tromboembolia pulmonar aguda (TEP) es un padecimiento grave. La ecocardiografía tridimensional (ECO-3D) es un método accesible, novedoso y preciso para cuantificar la función ventricular y auricular derechas. A la fecha, no existen suficientes estudios que evalúen su papel en esta entidad. Objetivo: Determinar la utilidad del ECO-3D en la evaluación de la función ventricular y auricular derecha, y el riesgo de complicaciones cardiovasculares en pacientes con TEP aguda. Material y métodos: Se analizaron 35 pacientes, admitidos al HC CMN SXXI con TEP por angioTAC, mediante equipo Phillips IE 33, se midieron parámetros bidimensionales (2D) y 3D relacionados con función ventricular y auricular derecha (TomTec y qlab 10). Se evaluaron complicaciones cardiovasculares intrahospitalarias. Resultados: El riesgo relativo de eventos cardiovasculares mayores combinados (ECMC) intrahospitalarios por ECO-3D fue: índice de esfericidad de la aurícula derecha > 1.32; RR 20.3 IC 95% 2.9-13.8; p = 0.0001, FEVD RR 7.3 IC 95% 2.5-20.9; p = 0.0001, VDFVD > 77 mL RR de 7.3 IC 95% 2.56-20.9; p = 0.0001, VSFVD RR 5.5 IC 95% 2.26-13.3; p = 0.0001. El análisis multivariado mostró tres predictores de riesgo independiente: índice de esfericidad de la aurícula derecha > 1.32, TEP masiva y presión arterial media. Conclusiones: La evaluación combinada mediante ecocardiografía 3D de función ventricular y auricular derechas permiten una evaluación cuantitativa, predicción del riesgo para la presentación de complicaciones cardiovasculares y tiempo de estancia intrahospitalarios en pacientes con TEP aguda.

Introduction: Acute pulmonary embolism (PE) is a serious condition. Tridimensional Ecocardiography (3D ECHO) is an accessible, novel and accurate method for determination of right ventricular and atrial function. To date there are insufficient studies to assess their role in this entity. Objective: Determine the usefulness of ECO-3D in evaluating right atrial and ventricular function, and the risk of cardiovascular complications in patients with acute PE. Material and methods: 35 patients were admitted to the HC CMN SXXI with PE by CT angiogram, we analized 2D and 3D parameters by Philips iE33, right atrial and ventricular function (TomTec and QLAB 10). Hospital cardiovascular complications were evaluated. Results: The relative risk of major combined cardiovascular events for 3D ECHO was: right atrial sphericity index > 1.32; RR 20.3 95% CI 2.9-13.8; p = 0.0001, RVEF RR 7.3 95% CI 2.5-20.9; p = 0.0001, RVEDV> 77 mL RR 2.56 95% CI 7.3-20.9, p = 0.0001, RR 5.5 RVESV 95% CI 2.26-13.3; p = 0.0001. Multivariate analysis showed three independent risk predictors: right atrial sphericity index > 1.32, massive PE and mean arterial pressure. Conclusions: The combined assessment by 3D echocardiography right ventricular and atrial function allow a quantitative assessment, risk prediction for cardiovascular complications and presentation of time-hospital stay in patients with acute PE.